For people with type 2 diabetes, switching to sulfonylurea drugs to control blood sugar levels is associated with an increased risk of complications compared with staying on the drug metformin, finds a study in The BMJ today.
Jul 18, 2018
0
37
The risk of having a heart attack while pregnant, giving birth, or during the two months after delivery, continues to increase for American women, a new study finds.
Jul 18, 2018
0
5
(HealthDay)—Higher maximal activated clotting time (ACT) is associated with a greater risk of major bleeding after transfemoral (TF) percutaneous coronary intervention (PCI) than after transradial (TR) PCI, according to ...
Jun 27, 2018
0
3
(HealthDay)—For adults with chronic obstructive pulmonary disease (COPD), acute exacerbations are associated with increased risk of myocardial infarction and ischemic stroke, according to a study published online May 3 ...
Jun 19, 2018
0
5
A very influential nutrition trial just tanked. It was retracted from the New England Journal of Medicine (NEJM) on 13 June, and re-published with new analyses and toned-down conclusions.
Jun 15, 2018
0
0
The heart of a neonatal mouse is capable of self-repair after tissue damage. However, this ability disappears during the first week of life. Researchers at the University of Helsinki investigate the molecular mechanisms underlying ...
Jun 1, 2018
0
46
(HealthDay)—Elevated fibroblast growth factor 23 (FGF-23) is associated with increased risk of recurrent major cardiovascular (CV) events in patients after an acute coronary syndrome (ACS), according to a study published ...
Apr 23, 2018
0
6
The formation of blood clots in atherosclerotic arteries results in myocardial infarction and stroke. New research at LMU now demonstrates that low doses of agents developed to treat leukemia can selectively inhibit atherosclerotic ...
Apr 10, 2018
0
5
The sun's radiation could be a factor in seasonal patterns of a deadly type of heart attack, according to new research that tracked a "summer shift" in their occurrence across seven countries.
Apr 9, 2018
0
114
(HealthDay)—Outcomes-based pricing does not reduce the costs of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, according to a research letter published online April 3 in the Annals of Internal Medicine.
Apr 3, 2018
0
3
